Altimmune, Inc.
ALT
NASDAQ·Healthcare·Biotechnology·Mkt cap $665.1M
$3.42
▲ +5.88%
P/E
-4.38
Mkt Cap
$665.1M
52-Wk Range
$2.56–$6.44
52-Week Range
$2.56 - $6.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 7.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual GLP-1/glucagon receptor agonist mechanism offering potential metabolic benefits beyond single-pathway competitors
- Immunotherapeutic approach to hepatitis B addressing chronic infection with differentiated mechanism of action
- Established clinical development infrastructure and regulatory experience in metabolic and infectious disease spaces
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Expanding obesity treatment market with growing demand for novel GLP-1 receptor agonist therapies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+25.3% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.12 vs -$0.14 consensus (+11.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.4%
Revenue trend · last 8Q
—
-86%
0%
0%
0%
+420%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$26.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 28, 2026
vs Industry
How ALT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related